Find summaries here of 3 recent studies conducted to shed light on difficult issues in the management of autosomal dominant polycystic kidney disease.
Overweight and obesity are independently associated with total kidney volume in children and young adults with ADPKD
Overweight/Obesity Risky in ADPKD. Increases in BMI among ADPKD patients parallels increases in the general population; a new study looked at whether overweight/obesity negatively affects the progression of ADPKD in younger patients as it does in adults. Marker of disease progression used was height-adjusted total kidney volume; average age of participants was 19 years.
Healthy Weight may Slow ADPKD Progression. Results: Median htTKV was greater in overweight/obese group vs normal weight (532 vs 316 mL/m; P=.01) and odds of above-median htTKV were increased after adjusting for demographic and disease/health-related factors (OR, 25.6; 95% CI, 2.1-333.3) Conclusions: Overweight/obesity is independently associated with increased htTKV in children and young adults with ADPKD. See Abstract SA-PO505
Real-world utilization of prescription medications to manage pain in patients with autosomal polycystic kidney disease
ADPKD Pain may be Disabling. >80% of ADPKD patients experience chronic or transient pain that ranges in severity from mild to disabling. A recent study assessed current use of prescription pain medications in this population. Patients: aged >18 yrs with continuous medical/pharmacy benefits for 6 months prior to Dx date (baseline) and 6 months after Dx date; 8,984 patients with ADPKD; mean age 57 yrs; 50% male.
50% ADPKD Patients Receive Opioids for Pain. Approximately 70% of ADPKD patients received 1 or more prescriptions for medications associated with pain relief and half of those received opioid analgesics.
Pain Rx Commmon in AKPKD. Treatment of pain with Rx medications common in ADPKD patients including high utilization of opioids and corticosteroids; use of NSAIDs* suggests higher severity of pain and warrants further study. See Abstract SA-PO472.
Patient and caregiver beliefs, attitudes, and perspectives on genetic screening and testing for autosomal polycystic kidney disease
Emotional Considerations in Genetic Screening. While genetic screening can prompt early diagnosis of ADPKD, the decision to go forward with testing can be difficult to make for patients and caregivers. Using focus groups and analyzing thematic content of discussions, the current study sought to capture the concerns of patients considering proceeding with genetic testing.
Themes Surrounding Decision Process. 5 themes around considering genetic testing were identified: Financial issues, unpredictability, poor decision autonomy and support, gaining control of well-being, and uncertainty of impact on quality of life impact.
Planning for the future. Genetic screening/testing is an opportunity for ADPKD patients to take ownership of health via family planning or preventive measures but there are myriad uncertainties around outcomes. Patient-centered genetic counseling and education could help reduce stress of decision making. See Abstract SA-PO494.
In the short slide show below you will find summaries of 3 recent studies conducted to shed light on difficult issues in the management of autosomal dominant polycystic kidney disease:
• The linkage of overweight/obesity to a marker of ADPKD severity and progression
• Real-world use of prescription medications for pain in patients with ADPKD
• Patient and caregiver perspectives on ADPKD genetic screening and testingÂ